Are MDT's R&D expenses trending sustainably?

Medtronic's (MDT) Research and Development (R&D) expenses have shown a general upward trend over the past three years, with some fluctuations. The company's commitment to innovation is reflected in the consistent increase in R&D spending, which is a positive sign for its long-term growth and sustainability.

1. **Growth Trend**: MDT's R&D expenses have risen from $2.7 billion in 2023 to $2.74 billion in 2024, and more recently, to $2.75 billion in 2025. This indicates a sustained and growing investment in R&D.
2. **Consistency**: The regularity of these increases suggests a strategic commitment to innovation and the development of new products and technologies, which is crucial for maintaining a competitive edge in the healthcare industry.
3. **Sustainability**: The fact that the increases in R&D spending have been maintained over time implies that MDT is managing its finances sustainably, prioritizing long-term growth over short-term gains.

|code|Ticker|Name|Date|R&D Expenses (FY) YoY|R&D Expenses (FY)|market_code|
|---|---|---|---|---|---|---|
|MDT|MDT.N|Medtronic|2022|10.148415563578018|2.746E9|169|
|MDT|MDT.N|Medtronic|2023|-1.820830298616169|2.696E9|169|
|MDT|MDT.N|Medtronic|2024|1.446587537091988|2.735E9|169|